Skip to main content
Loading

Vasomune Therapeutics Inc

February 26, 2024
Respiratory
Vasomune Therapeutics Inc
Vasomune Therapeutics Inc., is a clinical stage biopharma, with an asset in mid-phase 2a. AV-001, is a Tie-2 agonist that corrects vascular endothelial dysfunction and shows strong activity against life-threatening diseases such as pulmonary edema and Acute Respiratory Distress Syndrome. Vasomune has received more than $12M in non-dilutive funding from the US Department of Defense and Canadian National Research Council, as well as more than $15M in support from our co-development partner, AnGes Inc. We are raising $15M USD to support our clinical development program in ARDS, specifically phase 2b and manufacturing
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP